Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
85.62
-0.89 (-1.02%)
Feb 9, 2026, 9:33 AM EST - Market open

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
SPINRAZA Royalties Revenue
221.90M216.10M240.40M
SPINRAZA Royalties Revenue Growth
2.68%-10.11%-0.78%
WAINUA Royalties Revenue
43.00M20.20M-
WAINUA Royalties Revenue Growth
112.87%--
TEGSEDI and WAYLIVRA Revenue
36.90M34.20M34.90M
TEGSEDI and WAYLIVRA Revenue Growth
7.90%-2.01%15.95%
Commercial Licensing and Other Royalty Revenue
78.60M22.60M33.30M
Commercial Licensing and Other Royalty Revenue Growth
247.79%-32.13%7.42%
Total Commercial Revenue
380.40M293.10M308.60M
Total Commercial Revenue Growth
29.79%-5.02%1.71%
Amortization from Upfront Payments Revenue
-131.40M125.30M
Amortization from Upfront Payments Revenue Growth
-4.87%82.65%
Milestone Payments Revenue
-106.40M100.50M
Milestone Payments Revenue Growth
-5.87%35.81%
R&D License Fees Revenue
-71.30M116.80M
R&D License Fees Revenue Growth
--38.95%215.68%
Other R&D Services Revenue
-23.50M10.00M
Other R&D Services Revenue Growth
-135.00%-63.77%
Collaborative Agreement Revenue
510.00M332.60M352.60M
Collaborative Agreement Revenue Growth
53.34%-5.67%70.17%
Eplontersen Joint Development Revenue
76.40M79.40M126.40M
Eplontersen Joint Development Revenue Growth
-3.78%-37.18%64.58%
Total R&D Revenue
586.40M412.00M479.00M
Total R&D Revenue Growth
42.33%-13.99%68.66%
Revenue (Other)
-629.24M-432.16M-478.95M
Revenue (Total)
966.96M705.14M787.65M
Revenue (Total) Growth
37.13%-10.47%34.10%
Updated Oct 29, 2025. Data Source: Fiscal.ai.